Search research articles
Contact Us
Filters
Showing results (51-60 of 70) with videos related to
Page
of 7
Sort By:
Journal of Medical Virology
|
February 26, 2008
High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland
S Chlabicz, R Flisiak, O Kowalczuk, et al.
Przeglad Epidemiologiczny
|
January 1, 1991
[Incidence of so-called hepatic failure syndrome in relation to infection with hepatitis B virus (HBV) in epidemiological and environmental studies of the rural population in the Suwałki and Białystok regions 1978-1990]
P Boroń, A Borzuchowska, A Boroń-Kaczmarska, et al.
British Journal of Biomedical Science
|
August 13, 2019
Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals
M Łucejko, K Tomasiewicz, A Olczak, et al.
HIV Medicine
|
May 13, 2014
High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance
L Peters, A Mocroft, V Soriano, et al.
Journal of Viral Hepatitis
|
May 9, 2017
Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis
H Wedemeyer, A Craxí, E Zuckerman, et al.
Journal of Viral Hepatitis
|
June 12, 2018
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study
R Flisiak, E Janczewska, M Łucejko, et al.
Journal of Viral Hepatitis
|
November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
M Buti, R Flisiak, J-H Kao, et al.
HIV Medicine
|
October 7, 2017
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
A Cozzi-Lepri, R Zangerle, L Machala, et al.
HIV Medicine
|
February 9, 2019
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA
S Amele, L Peters, M Sluzhynska, et al.
Journal of Viral Hepatitis
|
August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
S Pianko, S Zeuzem, W-L Chuang, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 70) with videos related to
Sort By:
Page
of 7
Journal of Medical Virology
|
February 26, 2008
High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland
S Chlabicz, R Flisiak, O Kowalczuk, et al.
Przeglad Epidemiologiczny
|
January 1, 1991
[Incidence of so-called hepatic failure syndrome in relation to infection with hepatitis B virus (HBV) in epidemiological and environmental studies of the rural population in the Suwałki and Białystok regions 1978-1990]
P Boroń, A Borzuchowska, A Boroń-Kaczmarska, et al.
British Journal of Biomedical Science
|
August 13, 2019
Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals
M Łucejko, K Tomasiewicz, A Olczak, et al.
HIV Medicine
|
May 13, 2014
High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance
L Peters, A Mocroft, V Soriano, et al.
Journal of Viral Hepatitis
|
May 9, 2017
Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis
H Wedemeyer, A Craxí, E Zuckerman, et al.
Journal of Viral Hepatitis
|
June 12, 2018
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study
R Flisiak, E Janczewska, M Łucejko, et al.
Journal of Viral Hepatitis
|
November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
M Buti, R Flisiak, J-H Kao, et al.
HIV Medicine
|
October 7, 2017
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
A Cozzi-Lepri, R Zangerle, L Machala, et al.
HIV Medicine
|
February 9, 2019
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA
S Amele, L Peters, M Sluzhynska, et al.
Journal of Viral Hepatitis
|
August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
S Pianko, S Zeuzem, W-L Chuang, et al.
Page
of 7